Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp41871_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Termination of Share Buyback program
11 November, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that the Company’s share buyback program of up to $500 million announced on October 25, 2012, has today been terminated.
Since the initiation of the share buyback $300 million has been returned to shareholders, through the purchase of 9,823,536 shares at an average price of £19.46.
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX